Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges

The Lancet Neurology

Volumn 9, Issue 7, 2010, Pages 689-701

  Pantoni, Leonardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ATORVASTATIN; BIOLOGICAL MARKER; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; NIMODIPINE; PLACEBO; PRAVASTATIN; RIVASTIGMINE; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; ARTERIOLOSCLEROSIS; BLOOD CLOT LYSIS; BRAIN DAMAGE; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAROTID ENDARTERECTOMY; CEREBRAL SMALL VESSEL DISEASE; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITION; DEMENTIA; DISABILITY; DISEASE CLASSIFICATION; HUMAN; NEUROIMAGING; NEUROPATHOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROKE; VASCULAR AMYLOIDOSIS; VASCULAR SURGERY;

AGE FACTORS; ANTICOAGULANTS; BLOOD VESSELS; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; DIAGNOSTIC IMAGING; ENDARTERECTOMY, CAROTID; HUMANS; THROMBOLYTIC THERAPY;

EID: 77953533246     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70104-6     Document Type: Review

References (151)

1. Thompson C.S., and Hakim A.M. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 40 (2009) e322-e330
2. Pantoni L., Sarti C., Alafuzoff I., et al. Postmortem examination of vascular lesions in cognitive impairment. A survey among neuropathological services. Stroke 37 (2006) 1005-1009
3. Moody D.M., Brown W.R., Challa V.R., and Anderson R.L. Periventricular venous collagenosis: association with leukoaraiosis. Radiology 194 (1995) 469-476
4. Rowbotham G.F., and Little E. Circulation of the cerebral hemispheres. Br J Surg 52 (1965) 8-21
5. van den Bergh R. Centrifugal elements in the vascular pattern of the deep intracerebral blood supply. Angiologica 20 (1969) 88-98
6. De Reuck J. The human periventricular arterial blood supply and the anatomy of cerebral infarctions. Eur Neurol 5 (1971) 321-334
7. Pantoni L., and Garcia J.H. Pathogenesis of leukoaraiosis: a review. Stroke 28 (1997) 652-659
8. Hara K., Shiga A., Fukutake T., et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360 (2009) 1729-1739
9. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol 6 (2007) 149-161
10. Ballabio E., Bersano A., Bresolin N., and Candelise L. Monogenic vessel diseases related to ischemic stroke: a clinical approach. J Cereb Blood Flow Metab 27 (2007) 1649-1662
11. Razvi S.S., and Bone I. Single gene disorders causing ischaemic stroke. J Neurol 253 (2006) 685-700
12. Jennette J.C., and Falk R.J. Small-vessel vasculitis. N Engl J Med 337 (1997) 1512-1523
13. Dropcho E.J. Central nervous system injury by therapeutic irradiation. Neurol Clin 9 (1991) 969-988
14. Zipser B.D., Johanson C.E., Gonzalez L., et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28 (2007) 977-986
15. Furuta A., Nobuyoshi N., Nishihara Y., and Honie A. Medullary arteries in aging and dementia. Stroke 22 (1991) 442-446
16. Lammie G.A., Brannan F., Slattery J., and Warlow C. Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke 28 (1997) 2222-2229
17. Ogata J., Yamanishi H., and Pantoni L. Neuropathology of ischemic brain injury. In: Fisher M. (Ed). Handbook of Clinical Neurology, vol 92 (3rd series), Stroke Part I: Basic and epidemiological aspects (2009), Elsevier, Edinburgh 93-116
18. Ho K.-L., and Garcia J.H. Neuropathology of small blood vessels in selected diseases of the cerebral white matter. In: Pantoni L., Inzitari D., and Wallin A. (Eds). The matter of white matter. Clinical and pathophysiological aspects of white matter disease related to cognitive decline and vascular dementia (2000), Academic Pharmaceutical Productions, Utrecht, The Netherlands 247-273
19. Pantoni L., and Lammie A. Cerebral small vessel disease: pathological and pathophysiological aspects in relation to vascular cognitive impairment. In: Erkinjuntti T., and Gauthier S. (Eds). Vascular cognitive impairment (2002), Martin Dunitz Ltd, London 115-133
20. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 18 (1987) 311-324
21. Vonsattel J.P., Myers R.H., Hedley-Whyte E.T., Ropper A.H., Bird E.D., and Richardson E.P. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 30 (1991) 637-649
22. Jellinger K.A., and Attems J. Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathol 105 (2003) 14-17
23. Haglund M., Sjobeck M., and Englund E. Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 18 (2004) 132-137
24. Coria F., and Rubio I. Cerebral amyloid angiopathies. Neuropathol Appl Neurobiol 22 (1996) 216-227
25. McCarron M.O., and Nicoll J.A. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 3 (2004) 484-492
26. Smith E.E., and Eichler F. Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol 63 (2006) 148-151
27. Koennecke H.C. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 66 (2006) 165-171
28. Viswanathan A., and Chabriat H. Cerebral microhemorrhage. Stroke 37 (2006) 550-555
29. Gray F., Dubas F., Roullett E., and Escourelle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 18 (1985) 54-59
30. Imaoka K., Kobayashi S., Fujihara S., Shimode K., and Nagasaki M. Leukoencephalopathy with cerebral amyloid angiopathy: a semiquantitative and morphometric study. J Neurol 246 (1999) 661-666
31. Kimberly W.T., Gilson A., Rost N.S., et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 72 (2009) 1230-1235
32. Hainsworth A.H., and Markus H.S. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab 28 (2008) 1877-1891
33. Greenberg S.M., Nandigam R.N., Delgado P., et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke 40 (2009) 2382-2386
34. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 13 suppl 2 (2002) 7-10
35. Pantoni L., Garcia J.H., and Gutierrez J.A. Cerebral white matter is highly vulnerable to ischemia. Stroke 27 (1996) 1641-1647
36. Petito C.K., Olarte J.P., Roberts B., Nowak Jr. T.S., and Pulsinelli W.A. Selective glial vulnerability following transient global ischemia in rat brain. J Neuropathol Exp Neurol 57 (1998) 231-238
37. Brun A., and Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 19 (1986) 253-262
38. Garcia J.H., Liu K.F., Ye Z.R., and Gutierrez J.A. Incomplete infarct and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke 28 (1997) 2303-2309
39. Fisher C.M. Lacunes: small, deep cerebral infarcts. Neurology 15 (1964) 774-784
40. Fisher C.M. Lacunar strokes and infarcts: a review. Neurology 32 (1982) 871-876
41. Millikan C., and Futrell N. The fallacy of the lacune hypothesis. Stroke 21 (1990) 1251-1257
42. Boiten J., and Lodder J. Lacunar infarcts. Pathogenesis and validity of the clinical syndromes. Stroke 22 (1991) 1374-1378
43. Wardlaw J.M., Sandercock P.A., Dennis M.S., and Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?. Stroke 34 (2003) 806-812
44. Tomimoto H., Akiguchi I., Wakita H., Lin J.X., and Budka H. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol 99 (2000) 26-30
45. Rosenberg G.A. Inflammation and white matter damage in vascular cognitive impairment. Stroke 40 3 suppl (2009) S20-S23
46. Simpson J.E., Ince P.G., Higham C.E., et al., for the MRC Cognitive Function and Ageing Neuropathology Study Group. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol 33 (2007) 670-683
47. Brown W.R., Moody D.M., Thore C.R., and Challa V.R. Apoptosis in leukoaraiosis. AJNR Am J Neuroradiol 21 (2000) 79-82
48. Greenberg S.M., Vernooij M.W., Cordonnier C., et al., for the Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 8 (2009) 165-174
49. Hachinski V.C., Potter P., and Merskey H. Leuko-araiosis. Arch Neurol 44 (1987) 21-23
50. Pullicino P., Ostrow P., Miller L., Snyder W., and Munschauer F. Pontine ischemic rarefaction. Ann Neurol 37 (1995) 460-466
51. Kwa V.I., Stam J., Blok L.M., and Verbeeten Jr. B. T2-weighted hyperintense MRI lesions in the pons in patients with atherosclerosis. Amsterdam Vascular Medicine Group. Stroke 28 (1997) 1357-1360
52. Pantoni L., Poggesi A., and Inzitari D. The relation between white matter lesions and cognition. Curr Opin Neurol 20 (2007) 390-397
53. van der Flier W.M., van Straaten E., Barkhof F., et al., for the LADIS study group. Small vessel disease and general cognitive function in non-disabled elderly: the LADIS study. Stroke 36 (2005) 2116-2120
54. Adachi T., Kobayashi S., Yamaguchi S., et al. MRI findings of small subcortical "lacunar-like" infarction resulting from large vessel disease. J Neurol 247 (2002) 280-285
55. Wardlaw J.M. What causes lacunar stroke?. J Neurol Neurosurg Psychiatry 76 (2005) 617-619
56. de Jong G., Kessels F., and Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke 33 (2002) 2072-2076
57. Bokura H., Kobayashi S., and Yamaguchi S. Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. J Neurol 245 (1998) 116-122
58. Hirabuki N., Fujita N., Fujii K., Hashimoto T., and Kozuka T. MR appearance of Virchow-Robin spaces along lenticulostriate arteries: spin-echo and two-dimensional fast low-angle shot imaging. AJNR Am J Neuroradiol 15 (1994) 277-281
59. Pullicino P.M., Miller L.L., Alexandrov A.V., and Ostrow P.T. Infraputaminal 'lacunes'. Clinical and pathological correlations. Stroke 26 (1995) 1598-1602
60. Rouhl R.P., van Oostenbrugge R.J., Knottnerus I.L., Staals J.E., and Lodder J. Virchow-Robin spaces relate to cerebral small vessel disease severity. J Neurol 255 (2008) 692-696
61. Norvving B. Long-term prognosis after lacunar infarction. Lancet Neurol 2 (2003) 238-245
62. Tatemichi T.K., Desmond D.W., Prohovnik I., et al. Confusion and memory loss from capsular genu infarction: a thalamocortical disconnection syndrome?. Neurology 42 (1992) 1966-1979
63. Miyao S., Takano A., Teramoto J., and Takahashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke 23 (1992) 1434-1438
64. Samuelsson M., Söderfelt B., and Olsson G.B. Functional outcome in patients with lacunar infarction. Stroke 27 (1996) 842-846
65. Yamamoto Y., Akiguchi I., Oiwa K., Hayashi M., Kasai T., and Ozasa K. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. Stroke 33 (2002) 297-305
66. Koga H., Takashima Y., Murakawa R., Uchino A., Yuzuriha T., and Yao H. Cognitive consequences of multiple lacunes and leukoaraiosis as vascular cognitive impairment in community-dwelling elderly individuals. J Stroke Cerebrovasc Dis 18 (2009) 32-37
67. Benisty S., Gouw A.A., Porcher R., et al. Location of lacunar infarcts correlates with cognition in a sample of non disabled subjects with age-related white matter changes: the LADIS study. J Neurol Neurosurg Psychiatry 80 (2009) 478-483
68. Vermeer S.E., Prins M.D., Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222
69. Vermeer S.E., Longstreth Jr. W.T., and Koudstaal P.J. Silent brain infarcts: a systematic review. Lancet Neurol 6 (2007) 611-619
70. Pantoni L. Not-so-silent infarcts. Lancet Neurol 2 (2003) 335
71. Hachinski V. World Stroke Day 2008: "Little Strokes, Big Trouble". Stroke 39 (2008) 2407-2408
72. Simoni M., Pantoni L., Pracucci G., et al. Prevalence of CT-detected cerebral abnormalities in an elderly Swedish population sample. Acta Neurol Scand 118 (2008) 260-267
73. Longstreth Jr. W.T., Bernick C., Manolio T.A., Bryan N., Jungreis C.A., and Price T.R. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 55 (1998) 1217-1225
74. Das R.R., Seshadri S., Beiser A.S., et al. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring study. Stroke 39 (2008) 2929-2935
75. Leary M.C., and Saver J.F. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 16 (2003) 280-285
76. Van Swieten J.C., Staal S., Kappelle L.J., Derix M.M., and van Gijn J. Are white matter lesions directly associated with cognitive impairment in patients with lacunar infarcts?. J Neurol 243 (1996) 196-200
77. Pantoni L. Leukoaraiosis: from an ancient term to an actual marker of poor prognosis. Stroke 39 (2008) 1401-1403
78. Pantoni L., and Garcia J.H. The significance of cerebral white matter abnormalities 100 years after Binswanger's report: a review. Stroke 26 (1995) 1293-1301
79. Pantoni L., and Inzitari D. Leukoaraiosis and cognitive impairment. In: Burns A., O'Brien J., and Ames D. (Eds). Dementia. 3rd edn. (2005), Edward Arnold Publishers, London 546-564
80. Frisoni G.B., Galluzzi S., Pantoni L., and Filippi M. The effect on cognition of white matter lesions in the elderly: small but detectable. Nat Clin Pract Neurol 3 (2007) 620-627
81. Gunning-Dixon F.M., and Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 14 (2000) 224-232
82. Ferro J.M., and Madureira S. Age-related white matter changes and cognitive impairment. J Neurol Sci 203-204 (2002) 221-225
83. Jokinen H., Kalska H., Mäntylä R., et al. White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry 76 (2005) 1229-1233
84. Prins N.D., van Dijk E.J., den Heijer T., et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 61 (2004) 1531-1534
85. Jokinen H., Kalska H., Ylikoski R., et al., for the LADIS group. Longitudinal cognitive decline in subcortical ischemic vascular disease-the LADIS study. Cerebrovasc Dis 27 (2009) 384-391
86. Schmidt R., Petrovic K., Ropele S., Enzinger C., and Fazekas F. Progression of leukoaraiosis and cognition. Stroke 38 (2007) 2619-2625
87. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C., and Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N Engl J Med 360 (2009) 2302-2309
88. Yaksuhiji Y., Nishiyama M., Yakushiji S., et al. Brain microbleeds and global cognitive function in adults without neurological disorder. Stroke 39 (2008) 3323-3328
89. O'Brien J.T., Erkinjuntti T., Reisberg B., et al. Vascular cognitive impairment. Lancet Neurol 2 (2003) 89-98
90. Hachinski V., Iadecola C., Petersen R.C., et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Impairment Harmonization Standards. Stroke 37 (2006) 2220-2241
91. Erkinjuntti T., Inzitari D., Pantoni L., et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59 (2000) 23-30
92. Román G.C., Erkinjuntti T., Wallin A., Pantoni L., and Chui H.C. Subcortical ischaemic vascular dementia. Lancet Neurol 1 (2002) 426-436
93. Inzitari D., Erkinjuntti T., Wallin A., del Ser T., Romanelli M., and Pantoni L. Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 903 (2000) 510-521
94. Pantoni L., Poggesi A., and Inzitari D. Cognitive decline and dementia related to cerebrovascular diseases: some evidence and concepts. Cerebrovasc Dis 27 suppl 1 (2009) 191-196
95. Guttmann C.R., Benson R., Warfield S.K., et al. White matter abnormalities in mobility-impaired older persons. Neurology 54 (2000) 1277-1283
96. Baloh R.W., Ying S.H., and Jacobson K.M. A longitudinal study of gait and balance dysfunction in normal older people. Arch Neurol 60 (2003) 835-839
97. Baezner H., Blahak C., Poggesi A., et al., for the LADIS study group. Association of gait and balance disorders with age-related white matter changes-the LADIS study. Neurology 70 (2008) 935-942
98. O'Brien J., Desmond P., Ames D., et al. A magnetic resonance imaging study of white matter lesions in depression and Alzheimer's disease. Br J Psychiatry 168 (1996) 477-485
99. O'Brien J., Ames D., Chiu E., et al. Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ 317 (1998) 982-984
100. Poggesi A., Pracucci G., Chabriat H., et al., for the LADIS study group. Urinary complaints in non-disabled elders with age-related white matter changes: the LADIS study. J Am Geriatr Soc 56 (2008) 1638-1643
101. Pantoni L., Basile A.M., Pracucci G., et al., for the LADIS study group. Impact of age-related cerebral white matter changes on the transition to disability. The LADIS (Leukoaraiosis And DISability in the elderly) study: rationale, design and methodology. Neuroepidemiology 24 (2005) 51-62
102. Inzitari D., Simoni M., Pracucci G., et al., for the LADIS study group. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med 167 (2007) 81-88
103. Inzitari D., Pracucci G., Poggesi A., et al., for the LADIS study group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 339 (2009) b2477
104. Bamford J., Sandercock P., Jones L., and Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 18 (1987) 545-551
105. Petty G.W., Brown R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., and Wiebers D.O. Ischemic stroke subtypes. A population-based study of functional outcome, survival, and recurrence. Stroke 31 (2000) 1062-1068
106. Sacco S.E., Whisnant J.P., Broderick J.P., Phillips S.J., and O'Fallon W.M. Epidemiological characteristics of lacunar infarcts in a population. Stroke 22 (1991) 1236-1241
107. Kolominsky-Rabas P.L., Weber M., Gefeller O., Neuendorfer B., and Heuschmann P.U. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes, a population based study. Stroke 32 (2001) 2735-2740
108. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol 8 (2008) 222-228
109. Cocho D., Belvís R., Martí-Fàbregas J., et al. Does thrombolysis benefit patients with lacunar syndrome?. Eur Neurol 55 (2006) 70-73
110. Adams Jr. H.P., del Zoppo G., Alberts M.J., et al., for the American Heart Association/American Stroke Association Stroke Council, American Heart Association/American Stroke Association Clinical Cardiology Council, American Heart Association/American Stroke Association Cardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease Working Group, Quality of Care Outcomes in Research Interdisciplinary Working Group. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115 (2007) e478-e534
111. Wahlgren N., Ahmed N., Eriksson N., et al., for the Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 39 (2008) 3316-3322
112. Neumann-Haefelin T., Hoelig S., Berkefeld J., et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 37 (2006) 2463-2466
113. Palumbo V., Boulanger J.M., Hill M.D., Inzitari D., Buchan A.M., and for the CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 68 (2007) 1020-1024
114. Hacke W., Kaste M., Bluhmki E., et al., for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
115. Streifler J.Y., Eliasziw M., Benavente O.R., et al., for the North American Symptomatic Carotid Endarterectomy Trial Group. Prognostic importance of leukoaraiosis in patients with symptomatic internal carotid artery stenosis. Stroke 33 (2002) 1651-1655
116. Lin R., Svensson L., Gupta R., Lytle B., and Krieger D. Chronic ischemic cerebral white matter disease is a risk factor for nonfocal neurologic injury after total aortic arch replacement. J Thorac Cardiovasc Surg 133 (2007) 1059-1065
117. Gorter J.W., for the Stroke Prevention in Reversible Ischemia Trial (SPIRIT), and European Atrial Fibrillation Trial (EAFT) Study Groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 53 (1999) 1319-1327
118. Smith E.E., Rosand J., Knudsen K.A., Hylek E.M., and Greenberg S.M. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 59 (2002) 193-197
119. Grips E., Sedlaczek O., Bäzner H., Fritzinger M., Daffertshofer M., and Hennerici M. Supratentorial age-related white matter changes predict outcome in cerebellar stroke. Stroke 36 (2005) 1988-1993
120. Galluzzi S., Lanni C., Pantoni L., Filippi M., and Frisoni G.B. White matter lesions in the elderly: pathophysiological hypothesis on the effect on brain plasticity and reserve. J Neurol Sci 273 (2008) 3-9
121. Greenberg S.M. Small vessels, big problems. N Engl J Med 354 (2006) 1451-1453
122. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14 (1983) 5-14
123. Gent M., Blakely J.A., Easton J.D., et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1 (1989) 1215-1220
124. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 349 (1997) 1641-1649
125. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral ischemia. J Stroke Cerebrovasc Dis 9 (2000) 147-157
126. Amarenco P., Benavente O., Goldstein L.B., et al., for the SPARCL Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 40 (2009) 1405-1409
127. Pérgola P.E., White C.L., Graves J.W., et al., for the SPS3 Investigators. Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study. Blood Press Monit 12 (2007) 1-8
128. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
129. Wilcock G., Möbius H.J., Stöffler A., and for the MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17 (2002) 297-305
130. Auchus A.P., Brashear H.R., Salloway S., Korczyn A.D., De Deyn P.P., Gassmann-Mayer C., and for the GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: a randomized trial. Neurology 69 (2007) 448-458
131. Pantoni L., Carosi M., Amigoni S., Mascalchi M., and Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacology 19 (1996) 497-506
132. Pantoni L., Rossi R., Inzitari D., et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 175 (2000) 124-134
133. Pantoni L., Del Ser T., Soglian A.G., et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36 (2005) 619-624
134. Dichgans M., Markus H.S., Salloway S., et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 7 (2008) 310-318
135. Jokinen H., Kalska H., Ylikoski R., et al., for the LADIS group. MRI-defined subcortical ischemic vascular disease: baseline clinical and neuropsychological findings. The LADIS study. Cerebrovasc Dis 27 (2009) 336-344
136. Ylikoski R., Jokinen H., Andersen P., et al., for the LADIS study group. Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS study. Dement Geriatr Cogn Disord 24 (2007) 73-81
137. Moretti R., Torre P., Antonello R.M., Cazzato G., and Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 203-204 (2002) 141-146
138. Moretti R., Torre P., Antonello R.M., Cazzato G., and Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 18 (2003) 265-272
139. Ballard C., Sauter M., Scheltens P., et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 24 (2008) 2561-2574
140. Schmidt R., Scheltens P., Erkinjuntti T., et al., for the European Task Force on Age-Related White Matter Changes. White matter lesion progression. A surrogate endpoint for trials in cerebral small vessel disease. Neurology 63 (2004) 139-144
141. Dufouil C., Chalmers J., Coskun O., et al., for the PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 112 (2005) 1644-1650
142. ten Dam V.H., van den Heuvel D.M., van Buchem M.A., et al., for the PROSPER Study Group. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 64 (2005) 1807-1809
143. Mok V.C., Lam W.W., Fan Y.H., et al. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 256 (2009) 750-757
144. Hannesdottir K., Nitkunan A., Charlton R.A., Barrick T.R., MacGregor G.A., and Markhus H.S. Cognitive impairment and white matter damage in hypertension: a pilot study. Acta Neurol Scand 119 (2009) 261-268
145. Schmidt R., Enzinger C., Ropele S., Schmidt H., Fazekas F., and for the Austrian Stroke Prevention Study. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 361 (2003) 2046-2048
146. Longstreth Jr. W.T., Arnold A.M., Beauchamp Jr. N.J., et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 36 (2005) 56-61
147. Sachdev P., Wen W., Chen X., and Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 68 (2007) 214-222
148. Gouw A.A., van der Flier W.M., Fazekas F., et al., for the LADIS study group. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 39 (2008) 1414-1420
149. Pieters B., Staals J., Knottnerus I., et al. Periventricular white matter lucencies relate to low vitamin B12 levels in patients with small vessel stroke. Stroke 40 (2009) 1623-1626
150. Jonsson M., Zetterberg H., van Straaten E., et al. Cerebrospinal fluid biomarkers of white matter lesions-cross-sectional results from the LADIS study. Eur J Neurol 17 (2010) 377-382
151. Sjögren M., Blomberg M., Jonsson M., et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66 (2001) 510-516